Delcath Systems, Inc.

NASDAQ:DCTH

Medical - Devices

Healthcare
$19.70 -1.91%

-$0.23 today

Market cap
$685.32M
Beta
0.52
P/E (TTM)
751.4
EPS (TTM)
$0.02
52W Low $8.12High $14.48

Volume 0.59M

Average 0.42M

DCTH Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Delcath Systems, Inc.NASDAQ: DCTH

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash dips below year-ago levels

Q1 FY2026 net change in cash of $2.14M (cash outflow) fell 89.1% year over year, behind the +2854.1% change in trailing-twelve-month net change in cash.

Context

  • Net change in cash amounted to 13.0% of revenue in FY2025, down 40.0 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -89.1% toward the trailing-twelve-month pace of +2854.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.14M-230.5% QoQ
Last fiscal yearDec 2025
$11.04M-44.0% YoY
LTMMar 2026
$28.54M+2854.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.1%——
1 year-44.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
11.04M USD
Year-over-year change
-44.0%

Net Change in Cash vs competitors

How DCTH compares with its peers on the latest reported figures

  • DCTH's LTM Mar 2026 net change in cash of $28.54M is the 3rd largest of the 4 companies compared; the peer median is $9.57M.
  • Its year-over-year change of +2854.1% is the highest of 4, against a peer median of +109.8%.
  • Net change in cash amounts to 31.6% of revenue for DCTH, versus a peer median of 97.0%.
DCTH Competitors Peer median
Net Change in Cash for DCTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$43.55M +382.3%—97.0%
NVCRNovoCure LimitedLTM Mar 2026$32.11M -90.2%-12.6%4.8%
DCTHDelcath Systems, Inc.LTM Mar 2026$28.54M +2854.1%—31.6%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$9.57M +109.8%—1547.9%
Peer median (excluding DCTH) $9.57M+109.8%-12.6%97.0%

Competitors are the stored peer set for DCTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(25.65M)(36.51M)(47.68M)(26.39M)2.7M
Depreciation & Amortization146K132K128K229K349K
Deferred Income Tax00000
Stock-Based Compensation7.83M7.94M8.15M9.77M24.23M
Change in Working Capital(5.76M)2.11M(906K)(15.52M)(3.07M)
Accounts Receivables13K(322K)125K(10.65M)(854K)
Inventory(557K)(587K)(1.32M)(3.61M)(3.32M)
Accounts Payables(1.14M)1.8M(199K)479K4.77M
Other Working Capital(4.08M)1.23M492K(1.74M)(3.66M)
Other Non-Cash Items831K1.37M9.05M13.23M(1.7M)
Operating Cash Flow(22.6M)(24.95M)(31.25M)(18.68M)22.52M
Capital Expenditures(143K)(209K)(58K)(559K)(1.55M)
Acquisitions (Net)00000
Purchases of Investments00(19.65M)(52.45M)(93.22M)
Sales of Investments00052.03M68.17M
Other Investing Activities00000
Investing Cash Flow(143K)(209K)(19.71M)(981K)(26.59M)
Debt Repayment14.44M(714K)(6.31M)(10.61M)0
Common Stock Issued3.92M10.86M23.08M7.02M21.05M
Common Stock Repurchased0000(6M)
Dividends Paid00000
Other Financing Activities2.46M035.01M43M0
Financing Cash Flow20.82M10.14M51.78M39.41M15.05M
Effect of Forex Changes122K(115K)56K(32K)68K
Net Change in Cash(1.8M)(15.13M)874K19.72M11.04M
Free Cash Flow(22.75M)(25.16M)(31.31M)(19.24M)20.97M

Delcath Systems, Inc.

NASDAQ:DCTH

Intrinsic Alpha fair value

Locked

Current Price

$19.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.